Colon cancer tumorigenesis initiated by the H1047R mutant PI3K

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Yueh, Alexander E ^a   Payne, Susan N ^b   Leystra, Alyssa A ^c   Van De Hey, Dana R ^a   Foley, Tyler M ^a   Pasch, Cheri A ^b   Clipson, Linda ^c   Matkowskyj, Kristina A ^a,b,d   Deming, Dustin A ^a,b,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; DACTOLISIB; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, MOUSE; PIK3CA PROTEIN, MOUSE; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SIZE; COLON ADENOCARCINOMA; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOGENESIS; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MISSENSE MUTATION; PATHOLOGY; TRANSGENIC MOUSE; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; IMIDAZOLES; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; TOR SERINE-THREONINE KINASES; TUMOR BURDEN;

EID: 84959378791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148730     Document Type: Article

References (30)

1. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000; 18:1967-79. PMID: 10784639
2. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 1997; 386:761, 3. PMID: 9126728
3. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 2006; 25:7531-7. PMID: 17143297
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759-67. PMID: 2188735
5. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009; 361:2449-60. doi: 10.1056/NEJMra0804588 PMID: 20018966
6. Je IJ, Vermeulen L, Meijer GA, Dekker E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol. 2015; 12:401-9. doi: 10.1038/nrgastro.2015.73 PMID: 25963511
7. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554. PMID: 15016963
8. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2:489-501. PMID: 12094235
9. Zhao L, Vogt PK. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle. 2010; 9:596-600. PMID: 20009532
10. Leystra AA, Deming DA, Zahm CD, Farhoud M, Olson TJ, Hadac JN, et al. Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res. 2012; 72:2931-6. doi: 10.1158/0008-5472. CAN-11-4097 PMID: 22525701
11. Wong MH, Saam JR, Stappenbeck TS, Rexer CH, Gordon JI. Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. Proc Natl Acad Sci U S A. 2000; 97:12601-6. PMID: 11050178
12. Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG, et al. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res. 2011; 71:2706-17. doi: 10.1158/0008-5472.CAN-10-0738 PMID: 21324922
13. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992; 256:668-70. PMID: 1350108
14. Deming DA, Leystra AA, Nettekoven L, Sievers C, Miller D, Middlebrooks M, et al. PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene. 2014; 33:2245-54. doi: 10.1038/onc.2013.167 PMID: 23708654
15. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14:1351-6. doi: 10.1038/nm.1890 PMID: 19029981
16. Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, Albrecht D, et al. mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. PLoS One. 2013; 8:e60709. doi: 10.1371/journal.pone.0060709 PMID: 23593290
17. Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, et al. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res. 2011; 17:7634-44. doi: 10.1158/1078-0432.CCR-11-1677 PMID: 22038997
18. Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol. 2015; 23:98-107. doi: 10.1016/j.coph.2015.05.016 PMID: 26117819
19. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370:1008-18. doi: 10.1056/NEJMoa1314583 PMID: 24450858
20. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013; 73:276-84. doi: 10.1158/0008-5472.CAN-12-1726 PMID: 23066039
21. Rodon J, Juric D, Gonzalez-Angulo AM, Bendell J, Berlin J, Bootle D, et al. Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. Cancer Res. 2013; 73.
22. Rodrigues HV, Lim J, Stephen B, Janku F, Tsimberidou AM, Piha-Paul SA, et al. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. J Clin Oncol. 2015; 33.
23. Pena CE, Jeffers M, Genvresse I, Appleman LJ, Ramanathan RK, Patnaik A. Biomarker analysis from a Phase I study of copanlisib with expansion cohorts in solid tumors with and without PIK3CA mutations and NHL. J Clin Oncol. 2015; 33.
24. Moore KN, Varghese AM, Hyman DM, Callies S, Lin J, Wacheck V, et al. A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer. J Clin Oncol. 2015; 33.
25. Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF. Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila). 2010; 3:1542-51.
26. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008; 118:3065-74. doi: 10.1172/JCI34739 PMID: 18725988
27. Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, et al. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci U S A. 2013; 110:21124-9. doi: 10.1073/pnas.1314124110 PMID: 24327733
28. Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, et al. PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis. In press.
29. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008; 10:534-41. PMID: 18516290
30. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319:525-32. PMID: 2841597